A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer

Clinical Cancer Research

Volumn 11, Issue 15, 2005, Pages 5526-5533

  Mackay, Helen ^a   Hedley, David ^a   Major, Pierre ^a   Townsley, Carol ^a   Mackenzie, Mary ^a   Vincent, Mark ^a   Degendorfer, Pam ^a   Tsao, Ming Sound ^a   Nicklee, Trudey ^a   Birle, Diana ^a   Wright, John ^b   Siu, Lillian ^a   Moore, Malcolm ^a   Oza, Amit ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; BORTEZOMIB; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LOPERAMIDE; OXALIPLATIN; PROTEASOME INHIBITOR; PROTEIN P53; SERINE; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DYSPNEA; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; LYMPHOCYTOPENIA; MALE; METASTASIS; MOTOR NEUROPATHY; MOUSE; MYALGIA; NAUSEA; NEUROTOXICITY; NONHUMAN; PAIN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR GROWTH; TUMOR XENOGRAFT; VOMITING;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BIOPSY; BORONIC ACIDS; CARBONIC ANHYDRASES; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; LIVER; MALE; MICROCIRCULATION; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NF-KAPPA B; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SERINE; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 23044431754     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0081     Document Type: Article

References (25)

1. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:123-37.
2. Goldberg AL, Stein R, Adams J. New insights into proteasome function: from Archaebacteria to drug development. Chem Biol 1995;2:503-8.
3. Palombella VJ, Rando OJ, Goldberg AL, Manniatis T. The ubiquitin-proteasome pathway is required for processing the NF-κB. Cell 1994;78:773-85.
4. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Manniatis T, Collins T. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 1995;2:493-506.
5. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996;274:782-4.
6. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001;20:4188-97.
7. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J Biol Chem 1999;274:6519-25.
8. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60.
9. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-45.
10. Vukovic V, Haughland HK, Nicklee T, Morrison AJ, Hedley DW. Hypoxia-inducible factor-1 α an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res 2001;61:7394-8.
11. Hedley D, Pintilie M, Woo J, et al. Carbonic anhydrase IX expression, hypoxia and prognosis patients with uterine and cervical carcinoma. Clin Cancer Res 2003;9:5666-74.
12. Olive PL, Aquino-Parsons C, MacPhail SH, et al. Carbonic anhydrase 1X as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 2001;61:8924-9.
13. Lord EM, Harwell L, Koch CJ. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res 1993;53:5721-6.
14. Jamal MAT, Samuels A, Ghafoor A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
15. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of Bortezomib in relapsed, refractory myeloma. NEJM 2003;348:2609-17.
16. Papandreou CN, Dalaini DD, Nix D, et al. Phase I trial of the proteasome inhibitor Bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22:2108-21.
17. Davis NB, Taber DA, Ansari RH, et al. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago Phase II Consortium study. J Clin Oncol 2004;22:115-9.
18. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11.
19. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002;109:S81-96.
20. Vermeulen L, De Wilde G, Van Damme P, et al. Transcriptional activation of the NF-κB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 2003;22:1313-24.
21. Harris AL. Hypoxia-a key regulating factor in tumor growth. Nat Rev Cancer 2002;2:38-47.
22. Nordsmark M, Loncaster J, Aquino-Parsons C, et al. Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix cancer. Radiother Oncol 2003;67:35-44.
23. Cusack JC, Liu R, Houstan M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res 2001;61:3535-40.
24. Russo SM, Tepper JE, Baldwin AS, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int J Radiat Oncol Biol Phys 2001;50:183-93.
25. Nawrocki S, Bruns C, Harbison M, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002;1:1243-53.